AbbVie Inc.
Company & revenue
About AbbVie Inc.
Who they are
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Detailed revenue, brand and relationship research has not yet been completed for ABBV.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
22
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
45
Weak
Financial Strength
55
Business Quality / Moat
23
Management
54
Growth Quality
35
Risk / Durability
72
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
32
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
38/100
Building Historical Record
Model Score 38/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for ABBV
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ABBV maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is ABBV's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is ABBV's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify ABBV's current valuation?
Essential Investment Snapshot
Wall Street Score
22
Opportunity Score
32
Market Cap
$464.35B
P/E Ratio
73.8
EPS
$3.55
52-Week High
$269.39
52-Week Low
$190.75
Beta
0.28
Intrinsic Value
$42.61
Analyst Target
$296.00
Shares Outstanding
1.77B
Total Revenue
$64.39B
Total Debt
$70.82B
Dividend Yield
2.63%
Liquidation Value / Share
$-3.31
Annual Dividend
$6.92
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ABBV
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Elevated debt risk
Negative shareholder equity • Total debt is at least one year of revenue • Cash covers less than 20% of total debt
Community Sentiment
0 active · 0 total callsNo personal call yet on ABBV.
What the Bulls Say
- +Product opportunity: AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases.
- +Product opportunity: SKYRIZI, which addresses moderate to severe plaque psoriasis in adults.
- +Product opportunity: and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthriti.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
No strong bearish data point is currently available.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
23
Sep 8, 2026
Change
-0.5
points
Current Score
22
Oct 1, 2026
Category Changes
ABBV decreased 0.5 points because Moat declined by 5.7 points.
Negative Contributors
- − Moat declined by 5.7 points
Projected Score
Projected Score
28
Projected Change
+5.2%
Preliminary comparable-period financial changes suggest improvement of approximately 5.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$262.82
Intrinsic Value
$42.61
Difference
+$220.21
+516.8% vs IV
Margin of Safety
-516.8%
Related Companies
Drug Manufacturers - GeneralNews
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
5 Solid Dividend Stocks to Buy Now
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial